-
Product Insights
NewOvarian Disease – Drugs In Development, 2024
Empower your strategies with our Ovarian Disease – Drugs In Development, 2024 report and make more profitable business decisions. Ovarian disease is a term for various conditions that affect the ovaries, which are the female reproductive organs that produce eggs and hormones. The most common ovarian diseases include polycystic ovary syndrome (PCOS), a hormonal disorder that causes irregular periods, excess androgen, and multiple cysts on the ovaries. PCOS can affect fertility and increase the risk of diabetes and heart disease. Another...
-
Product Insights
NewNasopharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Nasopharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose, an area called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking including hoarseness, recurrent ear infections, face pain or numbness, headache, hearing loss, and...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KVA-12123 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KVA-12123 in Ovarian Cancer Drug Details: KVA-12123 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NKTR-255 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NKTR-255 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) Drug Details: NKTR-255 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Porustobart in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Porustobart in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Melanoma Drug Details: HBM-4003 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Porustobart in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Porustobart in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Non-Small Cell Lung Cancer Drug Details: HBM-4003 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NN-1845 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NN-1845 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRAIN-002 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRAIN-002 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HRAIN-002 in Refractory Multiple Myeloma Drug Details:HRAIN-002 is under development for the...